All stakeholders win in a connected health ecosystem

In the Learning Health System, fragmented parts of the health ecosystem are connected so that data, information, and evidence can flow more efficiently.

This flow facilitates more rapid learning and enables us to progress on the goals we all share:

1. Improved quality of care
2. Reduced errors
3. Reduced costs
4. Faster impact of innovation (reduced time lag for knowledge translation)
What can pharma contribute to the Learning Health System?

1. Faster, patient-centered drug development
2. Clinical trial data
3. Real world evidence
4. Drug information
5. Deep disease state knowledge (e.g., non-branded health ed materials)
6. Continuing progress toward personalized medicine
7. Deep analytics expertise
8. Non-medical expertise such as knowledge management, other in the pre-competitive space (e.g., investigator databases)
9. Staffing
10. Funding
Opportunities for pharma in the Learning Health System

1. Faster, patient-centered drug development:
   • Design trials and real world studies to measure what patients value
   • Make clinical trials more convenient for patients
   • Increase enrollment in clinical trials
   • Make clinical trials a care option

2. Improved, appropriate access to data for...
   • Improved safety surveillance
   • Generating real world evidence
   • Enabling personalized medicine
   • Improved hypothesis generation

3. Appropriate and more efficient evidence dissemination:
   • Disseminate our clinical trial and real world evidence more efficiently as needed at the point of care
   • Reducing the appalling 17 year gap
   • Increasing the impact of innovation
How can pharma help create the Learning Health System?

1. Advance the LHS vision
2. Help plan and build
3. Spread the word – inside and out
4. Learn and prepare
1. **Advance the LHS vision:**
   - Raise awareness of the LHS in your organization
   - Secure executive advocacy
   - Coordinate your organization formally endorsing the LHS Core Values
   - Make a financial contribution to the Learning Health Community
   - Host a Learning Health System meeting at your HQ
How can pharma help create the Learning Health System? continued

2. Help plan and build:
   • Identify others in your organization who are interested; build a coalition in your organization to help progress the Learning Health System
   • Dedicate staff capacity to engage and contribute to Learning Health System initiatives, projects, task forces
   • Coordinate experts at your organization reviewing and commenting on the stakeholder tables (what needs to change so your organization can engage in the LHS?)
   • Coordinate experts at your organization reviewing and commenting on the LHS value proposition
3. **Spread the word – inside and out:**

- Spread the word when your company endorses the LHS Core Values
- Share key LHS articles and white papers, etc. internally
- Present internally on the LHS
- Connect other initiatives you are involved in to the LHS
- Post about the LHS on your organization’s social media sites
- Publish in *Learning Health Systems*
How can pharma help create the Learning Health System?

4. Learn and prepare:

- Attend LHS meetings
- Stay on top of published articles, books, and white papers on the LHS
- Inform your organization’s strategies, initiatives and projects (LHS as future context)
- Prepare your organization for an operational Learning Health System

Watch out: systems thinking may have its own effect... you may begin to form your own rapid learning loops internally
## Preparing your pharma co for the Learning Health System

<table>
<thead>
<tr>
<th>INITIATIVES</th>
<th>TIMEFRAMES</th>
<th>OBSTACLES / CHALLENGES</th>
<th>INFLUENCING FACTORS</th>
<th>DEPENDENCIES</th>
<th>PREREQUISITES</th>
<th>TECHNOLOGIES</th>
<th>REGULATIONS</th>
<th>FUNDING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adapt internal policies regarding sharing data and evidence</td>
<td>3 years total – 1 year for adoption</td>
<td>Consensus around regulatory and communication regarding internal policies</td>
<td>Pharma executives agreement</td>
<td>Establish priority with Quality and Compliance organizations</td>
<td>Updated/clarified regulations on pharma communication of data, info, and evidence in LHS</td>
<td>Minimal</td>
<td></td>
<td>Internal to company</td>
</tr>
<tr>
<td>Align on and adapt to LHS standards</td>
<td>4 years</td>
<td>Big impact on processes if standards are not aligned</td>
<td>Pharma executives agreement</td>
<td>ESTEL establishing standards in cooperation with pharma</td>
<td>ESTEL establishes standards and gap analysis</td>
<td>Executive advocate/sponsorship (may require sponsor initiative)</td>
<td></td>
<td>Internal to company</td>
</tr>
</tbody>
</table>


### Preparing your pharma co for the Learning Health System

<table>
<thead>
<tr>
<th>INITIATIVES</th>
<th>TIMEFRAMES</th>
<th>OBSTACLES / CHALLENGES</th>
<th>INFLUENCING FACTORS</th>
<th>DEPENDENCIES</th>
<th>PREREQUISITES</th>
<th>TECHNOLOGIES</th>
<th>REGULATIONS</th>
<th>FUNDING</th>
</tr>
</thead>
</table>
| * Increase speed of answering research questions (CT and RWE)             | ongoing    | * Internal inefficiencies  
* Internal capability gap in RWA and RWE  
* Data lag for certain types of R WD (claims)  
* Barriers to access to linked data (claims, specialty EMR, mobile data)  
* Overall timelines for CT execution from design to enrollment to dissemination  
* Scientific publication is the only means to quickly share CT and RWE that is off-label but may be very important to LHS | * Is it regulatory?  
* Pharma company resourcing RWE capability development | *  | * Collection of RCT measures in the context of clinical care/EMR network  
* Data warehouses that allow for seamless, rapid, and reliable linking across RWD types including data collected via web or mobile devices | * Update regulations on CTS | * |
| * Strengthen internal learning system                                      | *          | * Information overload  
* Lack of true reward system for continuous learning limits uptake  
* Employees span the globe  
* Potential conflict with initiatives that limit sharing of information beyond those with a clear need to know (e.g., Protect Lilly) | *  | *  | * Information system to efficiently scan and share knowledge corporately | *  | * |
Preparing your pharma co for the Learning Health System

<table>
<thead>
<tr>
<th>INITIATIVES</th>
<th>TIMEFRAMES</th>
<th>OBSTACLES / CHALLENGES</th>
<th>INFLUENCING FACTORS</th>
<th>DEPENDENCIES</th>
<th>PREREQUISITES</th>
<th>TECHNOLOGIES</th>
<th>REGULATIONS</th>
<th>FUNDING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adopt internal safety surveillance and risk evaluation and management strategies</td>
<td></td>
<td>Lack of nationally representative EMR data (there are initiatives ongoing with Truven claims)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adapt internal activities regarding understanding disease mechanism, progression, prevalence, and unmet need</td>
<td></td>
<td>Knowledge is siloed by department. Inefficiency in knowledge transfer as molecules step through clinical development phases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adapt internal CT planning and execution activities</td>
<td></td>
<td>Adaptations are seen as barriers to timely regulatory submission. Operational issues associated with adaptive design not well understood and thus adaptive designs are not readily embraced</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adapt internal activities regarding regulatory submission and inquiries (e.g., for ongoing benefit/risk assessments)</td>
<td></td>
<td>B/R analyses viewed as potentially limiting access of medications to patients rather than increasing access (emphasis in risk over benefit)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Preparing your pharma co for the Learning Health System

<table>
<thead>
<tr>
<th>INITIATIVES</th>
<th>TIMEFRAMES</th>
<th>OBSTACLES / CHALLENGES</th>
<th>INFLUENCING FACTORS</th>
<th>DEPENDENCIES</th>
<th>PREREQUISITES</th>
<th>TECHNOLOGIES</th>
<th>REGULATIONS</th>
<th>FUNDING</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Senior executive support and sponsorship of engagement with LHS</td>
<td>•</td>
<td>Potential skepticism as to the likelihood of LHS being developed in the US</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>• Adapt internal activities regarding understanding product usage and effectiveness post-launch</td>
<td>•</td>
<td>Access to RWD, especially OUS RWE development capability limited Comparative effectiveness perceived as a chance to lose It’s not required by the regulators, so do we go there? Lack of access to real-time RWD Ability to quickly modify DDL in response to learning from the field</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>• Build and coordinate internal centralized capability for access to and governance over RWD</td>
<td>•</td>
<td>Financial incentives for data vendors to enable this Unless RWD for research could be pre-competitive and shared Interoperability standards identified and consensual on them</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>• Develop internal platforms/infrastructure and tools to support use of RWD</td>
<td>•</td>
<td>RWD challenges in general Lack of easy to use data source agnostic tools</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>• Align policy engagements and activities with LHS</td>
<td>•</td>
<td></td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
</tbody>
</table>
Preparing your pharma co for the Learning Health System

<table>
<thead>
<tr>
<th>INITIATIVES</th>
<th>TIMEFRAMES</th>
<th>OBSTACLES / CHALLENGES</th>
<th>INFLUENCING FACTORS</th>
<th>DEPENDENCIES</th>
<th>PREREQUISITES</th>
<th>TECHNOLOGIES</th>
<th>REGULATIONS</th>
<th>FUNDING</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Adapt internal launch readiness activities</td>
<td></td>
<td>• Determined access to appropriate RWD for post-launch RWE prioritized as a key step for clinical development teams and as a performance measure for launch leader</td>
<td></td>
<td>• Ability to holistically plan CT and RW evidence</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Add/shift dedicated headcount to support LHS</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Develop strategies for value-based and indication-based contracting</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Manage culture change toward a knowledge sharing system</td>
<td>•</td>
<td></td>
<td>• Reward structure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Internal to company | | | | | | | | |

• Internal to company
### What needs to change for the pharma industry to engage in the LHS?

<table>
<thead>
<tr>
<th>INITIATIVES</th>
<th>TIMEFRAMES</th>
<th>OBSTACLES / CHALLENGES</th>
<th>INFLUENCING FACTORS</th>
<th>DEPENDENCIES</th>
<th>PREREQUISITES</th>
<th>TECHNOLOGIES</th>
<th>REGULATIONS</th>
<th>FUNDING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clarify rules of engagement regarding pharma communication</td>
<td>ASAP (within 2 years)</td>
<td>Industry must carefully follow regulations re communicating with patients, payers, and providers</td>
<td>Regulatory statutes and guidance</td>
<td>Policy alignment</td>
<td>Changes to (or increased clarity) to allow appropriate communication in LHS</td>
<td>Minimal (data security and privacy)</td>
<td>Need to adapt to allow engagement in LHS and global alignment around regulatory matters</td>
<td>FDA’s obligation to support</td>
</tr>
<tr>
<td>Ensure appropriate access and increase transparency about access to and co-use of de-identified data for research</td>
<td>PhRMA - Coordinate industry campaign around transparency – within 1 year after agreement</td>
<td>Achieving trust and expanding informed consent for data usage</td>
<td>•</td>
<td>•</td>
<td>Articulate how industry appropriately uses de-identified data for research; increase transparency</td>
<td>De-identification techs</td>
<td>HIPAA and other geographical policies regarding clinical data for research</td>
<td>•</td>
</tr>
<tr>
<td>Clarify IP protection</td>
<td>IP Group</td>
<td>Balance between sharing and openness and need to protect IP</td>
<td>Industry needs to provide guidance</td>
<td>•</td>
<td>•</td>
<td>Trust policies for IP protection in the LHS</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Decide as pharma industry what is pre-competitive</td>
<td>Guidance from TransCelerate team on timeframe to establish</td>
<td>Gain consensus across industry</td>
<td>Ala? TransCelerate TransCelerate outside of CTS</td>
<td>•</td>
<td>•</td>
<td>Trust and endorsement of de-identified data for co-use</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Continue to work across healthcare industry to standardize approaches to real world analytics</td>
<td>•</td>
<td>Gain consensus across healthcare ecosystem on RWA algorithms</td>
<td>RWE Team to validate timeline</td>
<td>•</td>
<td>Endorsement of standards by key professional societies, regulatory agencies</td>
<td>Need for flexible algorithms to define evidence based understanding of RWA</td>
<td>•</td>
<td>•</td>
</tr>
</tbody>
</table>
Thank you!

crawford_laura@lilly.com